Security key
127636207
Cadrenal Therapeutics, Inc. - Common Stock (CVKD)
CUSIP: 127636207
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 68,347
- Total 13F value
- $823,305
- Share change
- -957
- SEC-reported price per share
- $12.05
- Number of holders
- 14
- Value change
- -$12,430
- Number of buys
- 7
- Number of sells
- 6
- Shares outstanding
- 2,868,622
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
14
Top holders
10
CVKD full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Cadrenal Therapeutics, Inc. SEC filings
Cadrenal Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 127636207
Recent filing periods:
Ownership snapshot
Top reported holders of CVKD - Cadrenal Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Quang X. Pham
Disclosed value leader
Quang X. Pham
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G
3/4/5
13F
Lead comparable stake: 24%
13D/G row: Quang X. Pham
Showing 1-6 of 15 holder rows.
Quick read
Quang X. Pham leads the comparable SEC ownership view at 24%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Quang X. Pham's linked filing trail.
Comparable ownership
Top 5
Quang X. Pham
24%
648 A.s. Havlickova
4.4%
John R. Murphy
3%
VANGUARD GROUP INC
1.6%
GEODE CAPITAL MANAGEMENT, LLC
0.42%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Quang X. Pham |
13D/G
|
24%
|
$7,115,610
421,042 shares
|
$0 | 23 Jan 2025 |
| 648 A.s. Havlickova |
13D/G
Havlickova 648 a.s.
|
4.4%
|
$1,323,118
78,291 shares
|
$0 | 31 Dec 2024 |
| John R. Murphy |
13D/G
3/4/5
John Raymond Murphy · Director
|
3%
|
$899,164
53,205 shares
|
$0 | 31 Dec 2024 |
| VANGUARD GROUP INC |
13F
Company
|
1.6%
|
$804,510
45,633 shares
|
— | 31 Mar 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.42%
|
$213,075
12,086 shares
|
— | 31 Mar 2025 |
| UBS Group AG |
13F
Company
|
0.29%
|
$148,885
8,445 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
14
Shares
68,347
Rows available
14
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2026 Across Filers
Q1 2026 holders
17
Q2 2025 holders
14
Holder diff
-3
| Investor | Q1 2026 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend